摘要
嵌合抗原受体(chimeric antigen receptor,CAR)修饰的T细胞在血液系统恶性肿瘤的治疗中疗效显著。乳腺癌(breast cancer,BC)是全球女性近年来最常见的癌症,尽管手术、化学药物治疗、放射治疗、内分泌治疗以及靶向治疗的应用显著提升了BC的治愈率,但BC仍是女性恶性肿瘤死亡的主要原因。CAR-T细胞在BC体外和体内临床前研究中显示出有效的抗肿瘤功效。许多学者尝试将CAR-T细胞应用于BC,结果提示CAR-T细胞疗法可能是BC治疗的有效方法。
Chimeric antigen receptor(CAR)T-cells has gained remarkable effect in hematologic malignancy.Breast cancer(BC)is the most popular malignancy tumor in women.Although surgical treatment,radiotherapy,endocrine therapy and molecular targeted therapy increase cure ratio of BC,it is still the major cause for cancer death among women.CAR-T cells can promote anti-breast cancer activity in vivo and in vitro preclinical studies.At present,some studies attempt to push the boundary of CAR T-cell therapy in the BC area.The results indicate that CAR-T cells may be an effective method for BC.
作者
张晴
丁波泥
钱立元
吴唯
文言广
ZHANG Qing;DING Boni;QIAN Liyuan;WUWei;WEN Yanguang(Department of Breast and Thyroid Surgery,Third Xiangya Hospital,Central South University,Changsha 410013,China)
出处
《中南大学学报（医学版）》
CAS
CSCD
北大核心
2020年第9期1120-1126,共7页
Journal of Central South University ：Medical Science
关键词
嵌合抗原受体T细胞
乳腺癌
免疫治疗
chimeric antigen receptor T-cells
breast cancer
immunotherapy
